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Inflammatory responses, like all biological cascades, are shaped by a delicate balance between positive and
negative feedback loops. It is now clear that in addition to positive and negative checkpoints, the inflamma-
tory cascade rather unexpectedly boasts an additional checkpoint, a family of chemicals that actively
promote resolution and tissue repair without compromising host defense. Indeed, the resolution phase of
inflammation is just as actively orchestrated and carefully choreographed as its induction and inhibition. In
this review, we explore the immunological consequences of omega-3-derived specialized proresolving
mediators (SPMs) and discuss their place within what is currently understood of the role of the arachidonic
acid-derived prostaglandins, lipoxins, and their natural C15-epimers. We propose that treatment of inflam-
mation should not be restricted to the use of inhibitors of the acute cascade (antagonism) but broadened
to take account of the enormous therapeutic potential of inducers (agonists) of the resolution phase of
inflammation.Introduction
Infection and tissue injury drive the acute inflammatory
response, which, in its simplest form, is characterized by the
sequential release of mediators (including histamine, bradykinin,
and 5-hydroxytryptophan [5HT]), resulting in the immediate
influx of polymorphonuclear leukocytes (PMNs) followed by
phagocytosis via monocytes-macrophages, leading to leuko-
cyte clearance and resolution. Indeed, for the past 40 years,
research has focused on identifying factors that initiate and
perpetuate inflammation with the objective of developing anti-
inflammatory drugs to alleviate diseases driven by ongoing or
dysregulated inflammation. More recently, emphasis has shifted
to the other end of the inflammatory spectrum, i.e., resolution, in
order to understand how immune-mediated inflammatory re-
sponses are terminated.
The concept that antagonists that limit the duration of a bio-
logical cascade are generated at the same time that a cascade
is induced is very familiar in other self-limiting pathways of inter-
est to immunologists such the complement and coagulation
cascades. However, homeostasis takes an unexpected twist
in the inflammation cascade. Events at the onset of acute
inflammation establish biosynthetic circuits for a series of chem-
ical mediators that later not only serve as antagonists but also
serve as agonists; in other words, they don’t just inhibit the in-
flammatory cascade, they actively dismantle it, leading to the
restoration of tissue homeostasis and function. Anti-inflamma-
tion and proresolution are therefore not equivalent. The agonists
that actively promote resolution (an emerging family of prore-
solving lipid mediators including lipoxins, resolvins, and protec-
tins) are fundamentally different from the antagonists that limit
the duration and magnitude of the inflammatory response at
both the molecular and cellular levels (Ryan and Godson,
2010; Serhan, 2007). In this review we will explore the pathways,cells and molecules involved in curbing inflammation and which
begin the process of tissue repair. Advances in this area will help
shed light on why inflammation persists and provide drug devel-
opment opportunities based upon stimulating endogenous pro-
resolution mediators and their pathways, which act as agonists
along with the more traditional antagonists which are currently in
clinical use.
What Is Resolution and Who Are the Main Players?
The mediators and cell types involved in the active resolution
of acute inflammatory responses are emerging as important
determinants of the immune system’s status and function.
Inflammation does not switch off in a passive manner but in-
volves a program of unique pathways (Figure 1), mediators,
and cell subtypes (Serhan, 2007). It is important to note that
the cells can’t move without specific instructions—marching
orders—that in the acute inflammatory response come in the
form of chemical gradients of mediators (vide infra). Hence,
the focus on identification and decoding of the mediators of
the terminating events in the resolution of inflammation are of
considerable interest. At the tissue and cellular level, resolution
of inflammation has been defined, in broad terms, by the rate
of polymorphonuclear cell (PMN) clearance to the point when
they are absent from the site of primary tissue injury. The key
steps in this process include (1) clearance of the inciting stimuli,
(2) catabolism of local survival signals and silencing of intracel-
lular proinflammatory signaling pathways, (3) normalization of
chemokine gradients, apoptosis of PMNs, (4) their efferocytosis
by tissue and monocyte-derived macrophages, and (5) either
incorporation of these myeloid cells into the local population
or their recirculation via lymph or blood. Lipid mediators
(LM) including eicosanoids and the more recently discovered
omega-3 derived ‘‘specialized proresolution mediators’’ repre-
sent the key signaling molecules in this process (Figures 1Immunity 40, March 20, 2014 ª2014 Elsevier Inc. 315
Figure 1. Acute Inflammatory Response and the Role of Lipid Mediators in Resolution or Its Failure
Initiation of the acute response starts with changes in blood flow stimulated by PGE2 and PGI2, and LTB4, which are produced from arachidonic acid and stimulate
PMN recruitment. Excess prostaglandins and leukotrienes contribute to chronic inflammation. Cyclooxygenase (COX) production of PGD2 via human PGD2
synthase (hPGD2s) activates its receptor DP1, a GPCR that stimulates IL-10, an anti-inflammatory cytokine, which blocks the path to chronic inflammation. PGD2
can be converted to PGJ2 and 15-dPGJ2 to products that activate PPAR-g to activate resolution (see text for details).
Lipid mediator class switching is the temporal switch in inflammatory exudates that activates lipoxin production. LXA4 regulates MCP-1 and nonphlogistic
monocyte recruitment and stops LTB4-stimulated PMN influx. Lipoxins and resolvins limit further PMN influx to the site and stimulate efferocytosis and the
clearance of cellular debris by resolving macrophages. Resolvins, protectins, lipoxins, and maresins (SPM) stimulate and enhance efferocytosis and promote
resolution. Loss of any of the cell-type receptors or chemical mediators can in theory lead to failed resolution that might underlie the persistent inflammation
recognized as chronic inflammation associated with many diseases.
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return of affected tissues to homeostasis (Serhan, 2010; Serhan
et al., 2008).
The presence of specialized regulatory or proresolution cell
subsets including phagocytosing monocyte-derived macro-
phages and myeloid-derived suppressor cells, T regulatory cells
(Tregs), for instance, is also instrumental in helping switch off
inflammation in a nonphlogistic manner (D’Alessio et al., 2009).316 Immunity 40, March 20, 2014 ª2014 Elsevier Inc.Resolution and clearance of cellular debris from mucosal
surfaces involves the essential polyunsaturated fatty acids
(PUFA)-derived mediators including SPM that accomplish this,
as well as activate antimicrobial mechanisms in mucosal epithe-
lial cells (Colgan et al., 2013). Functionally, proresolving media-
tors and cell subtypes serve to act not merely as inflammatory
brakes but also facilitate the return of the site to homeostasis
in the process of catabasis: the return from disease state
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has classically been discussed in terms of either an insufficiency
or inadequacy leading to chronic inflammation, excess tissue
damage, and dysregulation of tissue healing including fibrosis
and has been implicated in multiple disease states (Serhan,
2007) including the development of autoimmunity (for reviews,
see Tabas and Glass, 2013).
Resolvins, Protectins, and Maresins: Specialized
Proresolving Mediators
Cells withinmulticellular responses require chemical gradients of
signals that instruct each to move and/or stop as needed
(Figure 1). In an acute inflammatory response, many chemical
signals are produced. Some are from microbial origins, whereas
others are biosynthesized by the host in response to tissue injury
and invasion (Majno and Joris, 2004). Among the chemical sig-
nals at the site of an acute inflammatory response, those that
originate from host essential fatty acids are of particular interest
because of their nutritional regulation of the response (Zhang
and Spite, 2012) and the potential to design small molecule
mimetics of these molecules (Serhan, 2007).
Chemical mediators biosynthesized from arachidonic acid
include prostaglandins and leukotriene B4, which are involved
in the initiating steps that permit white blood cells to leave the
postcapillary venules, i.e., diapedesis (Samuelsson et al., 1987;
Serhan, 2007). More recent research has focused on elucidating
chemical mediators and mechanisms involved in endogenous
anti-inflammation and its resolution (Levy et al., 2002; Serhan
et al., 2000). A systems approach with liquid chromatography-
tandem mass spectrometry (LC-MS/MS)-based lipidomics,
in vivo animal models, exudate cell trafficking, and functional
assessment with isolated human cells has uncovered bioactive
products identified within the resolution phase of acute sterile
inflammation (illustrated in top panel of Figure 1) that activate
proresolving mechanisms (Hong et al., 2003; Serhan et al.,
2000, 2002).
Focusing on self-limited resolving exudates also has permitted
a direct assessment of the host’s responses that enable the re-
turn to homeostasis. Key bioassays that have proven critical in
the initial studies focused on human neutrophil (PMN) transmi-
gration across endothelial cells and epithelial cells (Colgan
et al., 2013; Serhan et al., 2000) and the phagocytosis of cellular
debris and dead PMN (Majno and Joris, 2004). Attention focused
on these cellular responses because neutrophils are among the
first responders to injury and microbial invasion. The hypothesis
that endogenous chemical mediators are produced via cell-cell
interactions within developing inflammatory exudates (i.e., pus)
that control the size, magnitude, and duration of the exudate
turned out to be the case in animal models (Schwab et al.,
2007; Serhan et al., 2002). This approach has proven to be highly
relevant to human disease in that anti-PMN therapy (Takano
et al., 1998) has been shown to limit tissue damage and uncon-
trolled inflammation.
The historical milestones in resolution of inflammation from
observation of the gross cardinal signs of inflammation (Figure 1)
to active resolution to new therapeutics first in humans are an
exciting new area of investigation. In ancient medical texts of
the 11th and 12th century, the notion of treating inflammation
with ‘‘resolvents’’ as ‘‘mollificants’’ to help resolve disease was
already present. This concept of stimulating resolution of inflam-mation was apparently lost until the chemical structures of
endogenous mediators that stimulate resolution were finally
elucidated (Serhan et al., 2002). From this line of investigation
the resolvin, protectin, and maresin pathways were elucidated
and their functions in activating resolution of inflammation un-
covered. Within exudates resolving to homeostasis, the funda-
mental cellular processes proved predictive of the actions of
SPM in more complex animal disease models because the
cessation of PMN entry into tissue and removal of dead PMN,
as well as cellular debris, are central to all organs of the body
and many human disease pathologies. This is what makes pro-
resolving different from simple anti-inflammation or blocking
mediators and natural mechanisms in the host. It is now
apparent that a broad range of endogenous and exogenous
agents belong to the immunoresolvents (pharmacologic agents
or local endogenous mediators) that stimulate resolution of
inflammation in animal models and hopefully in human diseases
(Dalli et al., 2013a).
Of interest, the n-3 essential fatty acids EPA and DHA were
found to be substrates for the biosynthesis of potent anti-inflam-
matory proresolving endogenous mediators within inflammatory
resolving exudates (Hong et al., 2003; Serhan et al., 2002). Iden-
tification of omega-3 fatty acids as nutrients that activate prore-
solving mechanisms in inflammation has opened new areas of
investigation, because uncontrolled inflammation is now widely
appreciated to be a unifying theme and the fundamental basis
for many widely occurring diseases (Figure 1). It is worth noting
that there already exists a large body of literature addressing
the anti-inflammatory potential of EPA and DHA (for a recent re-
view, see Calder, 2013). Yet, the molecular basis by which these
essential fatty acids exert anti-inflammatory responses has re-
mained the subject of intense discussion. DHA and EPA have
many known critical functions in mammalian biology, and neither
EPA nor DHA is produced by humans to any great extent and
therefore must be absorbed within the diet (Calder, 2013). One
area where the function of DHA and its mechanism is clear is
the role of DHA in the retina. It has been argued that DHA is an
ancient molecule with functional roles in the brain and eye
imposed via evolutionary pressure (Crawford et al., 2013).
Thus, uncovering special chemical mediators biosynthesized
from n-3 fatty acids EPA, DHA, and DPA during self-limited in-
flammatory responses in the resolution phase of mouse exu-
dates with functions on individual human leukocytes has many
implications. For further mechanistic details on the biosynthesis
of the SPM (resolvins, protectins, and maresins), see recent re-
views covering their biosynthesis (Serhan, 2007), actions, and
total organic synthesis (Serhan and Petasis, 2011). In this review,
we focus on the SPM production in resolution and activities on
phagocytes and disease models relevant to acute inflammation
and the innate response.
Resolvins and Protectins
Specialized proresolving mediators (SPMs, Figures 1 and 2),
derived from different polyunsaturated fatty acid (omega-3
EPA and DHA) substrates, exert diverse biological effects on
immune function including the ability to counterregulate media-
tors that trigger leukocyte trafficking (Figures 1 and 2). Of the
essential polyunsaturated fatty acids, namely those that are
not biosynthesized de novo to any great extent in humans, the
omega-3 fatty acids such as DHA and EPA are supplied in theImmunity 40, March 20, 2014 ª2014 Elsevier Inc. 317
Figure 2. Time Course of Self-Limited Inflammatory Response and the Resolution n-3 Metabolome
Upper panel shows the ideal outcome for an acute challenge: edema, followed by PMN influx, then return to baseline and nonphlogistic recruitment of monocytes
andmacrophages for resolution. The temporal biosynthesis of SPM is initiated by leukocyte congregation within the exudate. In resolution phase, specificmiRNA
are regulated and some of these are controlled by resolvins in recent studies (see Li et al., 2013 and references within).
(legend continued on next page)
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Table 1. Resolvins and SPM in Resolution of Infections and
Increasing Survival in Murine Infections
Lipoxins,
Resolvins,
and Protectins
Increase
Survival Disease
Shorten
Resolution Reference
LXA4 O Bacterial
infections
Walker et al.
(2011)
15-epi- LXA4 O Lung injury El Kebir et al.
(2009)
RvE1 O Colitis + Arita et al. (2005)
O E. coli
peritonitis
+ Chiang et al.
(2012)
O Candida yeast + Haas-Stapleton
et al. (2007)
O Acid-induced
lung injury
+ Levy and Serhan
(2014)
RvD1, RvD5,
PD1
O E. coli
peritonitis
infection
+ Chiang et al.
(2012)
RvD1 O Acute lung
injury
+ Wang et al.
(2011)
RvD2 O Cecal ligation
and puncture
sepsis
+ Spite et al.
(2009)
O Burn wound
sepsis
+ Bohr et al. (2013)
Kurihara et al.
(2013)
Protectins O H1N1 viral
infections
Morita et al.
(2013)
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Reviewdiet (De Caterina, 2011). Marine oils are rich in both DHA and
EPA; in humans, DHA is concentrated in neural tissues including
brain and retina and is enriched in human milk, plasma, and
sperm, where their physical properties in the membrane bilayers
govern membrane fluidity (Calder, 2013; Crawford et al., 2013).
Within the immune system, PMN influx or chemotaxis occurs
along chemical gradients that are either from exogenous
sources (degradation products of microbial proteins and lipids
[e.g., LPS] or endogenous chemoattractants from the host
[chemokines, e.g., interleukin-8 (IL-8) and arachidonic acid-
derived leukotriene B4; see Figure 1, left side]). These endoge-
nous and exogenous factors also stimulate the nonphlogistic
recruitment of monocytes, which positively affect the efferocyto-
sis of apoptotic granulocytes (Figures 1 and 2). Thus, SPMs have
overlapping proresolving actions most likely arising from the
ability to bind and act as agonists on alternate SPM receptors
(e.g., RvD1 on the lipoxin A4 [LXA4] receptor [Wang et al.,
2011]). However, despite common actions, the source of dif-
ferent families of specialized proresolution mediators in inflam-
mation appears diverse. Recent evidence suggests that RvE1Lower panel shows resolving exudate. The E-series resolvins are biosynthesized
RvE1 via an epoxide intermediate, RvE2 and RvE3. D-series resolvin biosynthes
intermediate 17S-HpDHA is precursor to both protectin and D-series resolvins.
insertion initiated at the 14th carbon to biosynthesize maresin 1 (MaR1) via a
biosynthesis steps in human leukocytes and in mice are reviewed in Serhan (2
resolving actions are reviewed in Serhan and Petasis (2011). Apoptotic PMN res
Serhan, 2012). By definition, each SPM enhances efferocytosis and resolution
biosynthesis of other families of SPM. For example, RvE1 stimulates LXA4 produand RvE2 are biosynthesized by PMNs via the 5-LOX pathway
(Oh et al., 2011), whereas mouse eosinophils are responsible
for generation of 12/15-LOX-derived mediators PD1 and the
recently discovered RvE3 (Isobe et al., 2012; Yamada et al.,
2011). Deficiency of these cell types in tissues during the resolu-
tion phase might lead to impaired biosynthesis with deleterious
consequences (Yamada et al., 2011). The same might be the
case for the essential PUFAs (n-3 polyunsaturated fatty acids,
i.e., EPA and DHA) at the inflammatory site.
Functionally, SPMs enhance bacterial clearance by stimu-
lating mucosal production of bactericidal peptides (Colgan
et al., 2013), enhancing bacterial phagocytosis by PMNs and
macrophages and working synergistically with antibiotics to
enhance their therapeutic action and hence bacterial clearance
(Chiang et al., 2012). Importantly, despite encouraging resolu-
tion, they do not compromise host immune competence (Ser-
han, 2007; Spite et al., 2009). Several of the proresolving
mediators actually increase survival from infections in mouse
models of disease (bacterial and viral infections) (Table 1). For
instance, resolvin E1 (RvE1) administered prior to a murine
model of aspiration pneumonia (hydrochloric acid with subse-
quent Escherichia coli challenge) is associated with a reduction
in proinflammatory cytokines, decreased pulmonary PMN accu-
mulation, enhanced bacterial clearance, and improved survival
(Seki et al., 2010). Mechanistically, RvE1, at concentrations as
low as 1 nM, enhances macrophage phagocytosis (Hong et al.,
2008), as well as NADPH oxidase-mediated reactive oxygen
species (ROS) generation. Resolvins of the D-series appear
equally efficacious as RvE1 (Dalli et al., 2013a). Resolvin D1
(RvD1) treatment prior to LPS-induced acute lung injury
improves pathological indices and survival rates (Wang et al.,
2011) and might be equally effective in central nervous system
inflammation (Xu et al., 2013). The commonmechanism appears
to be suppression of NF-kB activation in a partly PPAR-g-depen-
dent manner, with associated reduction in downstream signaling
and alterations in transcriptomics (Arita et al., 2005; Liao et al.,
2012).
Resolvin D2 (RvD2), but not its isomer trans-RvD2, improves
survival in murine polymicrobial sepsis (cecal ligation and punc-
ture [CLP]) (Table 1). Its actions are multifaceted, targeting the
modulation of leukocyte-endothelial interactions directly (adhe-
sion receptor expression) and via stimulation of endothelial nitric
oxide (NO) production, altering the cytokine and eicosanoid pro-
files (reduced IL-17, IL-10, prostaglandin [PG]E2, and LTB4),
enhancing bacterial phagocytosis and intraphagosomal vacu-
olar production of ROS (Spite et al., 2009). Recently, the ability
of RvD2 to restore directionality to neutrophil migration and pre-
vent sepsis-induced immune dysfunction and thus increase sur-
vival from a secondary septic challenge after burn injury has
been demonstrated (Kurihara et al., 2013). Resolvin D3 appears
later in the resolution phase of peritonitis, displaying potentfrom EPA, initiated by oxygen insertion at the 18th carbon position to produce
is is initiated with oxygen insertion at the 17th carbon position of n-3 DHA. The
Human and mouse macrophages also convert DHA to maresins via oxygen
recently identified 13S,14S-epoxy-intermediate that also is bioactive. The
007), and stereochemical assignments with confirmation of their potent pro-
olution phase microparticles resolving macrophages produce SPM (Dalli and
in vivo in animal models; see text for details. Also, some SPM stimulate the
ction in mouse lung (Levy and Serhan, 2014).
Immunity 40, March 20, 2014 ª2014 Elsevier Inc. 319
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uptake of apoptotic cells (Dalli et al., 2013a). Hence, despite
being inherently anti-inflammatory and proresolution in nature,
SPMs exert diverse actions in host defense and pathogen inter-
actions (Table 1) in a manner that is, paradoxically, conducive to
optimal bacterial clearance and not immunosuppressive.
Maresins: Macrophage Mediators In Resolving
Inflammation and Organ Regeneration
From the study of resolution phase macrophages, a new
pathway able to produce potent mediators from DHA has been
uncovered and coined ‘‘maresins.’’ The stereochemical assign-
ments of maresin 1 (MaR1) and its related isomers have been
established (Serhan et al., 2012), as well as the key epoxide inter-
mediate (Figure 2, lower panel) in the maresin biosynthetic
pathway (Dalli et al., 2013b). MaR1 is produced by human mac-
rophages from endogenous DHA and is the newest pathway
and family of mediators identified. In these recent studies,
MaR1 was obtained andmatched to synthetic 7R,14S-dihydrox-
ydocosa-4Z,8E,10E,12Z,16Z,19Z-hexaenoic acid prepared by
total organic synthesis. MaR1 alcohol groups and Z/E geometry
of conjugated double bonds were assigned with isomers also
prepared by total organic synthesis and confirmed using NMR.
MaR1’s potent defining actions were confirmed with synthetic
MaR1, namely limiting neutrophil (PMN) infiltration in murine
peritonitis (ng/mouse range), as well as enhancing human
macrophage uptake of apoptotic PMNs. Leukocyte-derived mi-
croparticles contribute to the production of MaR1 and SPM in
that they stimulate efferocytosis (Figure 2), as well as provide
substrates and pathway intermediates in SPM biosynthesis to
recipient cell types (Dalli and Serhan, 2012).
The appearance of MaR1 in the inflammatory response can be
in the later stages with the entry of resolution phase macro-
phages that release maresins. MaR1 appears slightly more
potent than Resolvin D1 (RvD1) in stimulating human macro-
phage efferocytosis, an action not shared by prostaglandins or
leukotriene B4. MaR1 and RvE1 each accelerate tissue regener-
ation in planaria, increasing the rate of head reappearance. With
surgery or injury of planaria (when cut in half), MaR1 is bio-
synthesized from deuterium-labeled (d5)-DHA indicating that
this pathway is conserved in evolution from flatworm to humans
(Serhan et al., 2012). Blocking this pathway delays organ regen-
eration, and MaR1 rescues this primordial response of the
organism. MaR1 dose-dependently inhibited TRPV1 currents in
neurons, blocked capsaicin-induced inward currents (IC50 z
0.5 nM) and reduced both inflammatory and chemotherapy-
induced neuropathic pain in mice. MaR1’s potent anti-inflamma-
tory and proresolving actions were recently confirmed in murine
colitis, where it is protective in both DSS and TNBS models of
colitis (Marcon et al., 2013). Hence, MaR1 has multiple potent
actions in regulating inflammation resolution, tissue regenera-
tion, and resolving pain. These findings also suggest that shared
chemical signals occur in biological processes as diverse as
cellular trafficking in the resolution of inflammation to tissue
regeneration in worms.
In addition to the assignments of SPM stereochemistry of the
endogenous bioactive products (i.e., RvE1, RvD1, RvD2, RvD3,
etc.) and structure function with materials prepared by organic
synthesis (Serhan andPetasis, 2011), other groups have focused
on the synthesis of these molecules that are now commercially320 Immunity 40, March 20, 2014 ª2014 Elsevier Inc.available and expanded their roles and mechanisms in a range
of systems relevant to human biology. Recently, the total organic
synthesis of resolvins and MaR1 has also been achieved by
Rodriguez and Spur (2012). Kobayashi et al. also reported on
the total organic synthesis of protectin D1 and E-series resolvins
(Ogawa and Kobayashi, 2011). Total organic synthesis of 18-
HEPE, a precursor from 18-HpEPE of E-series resolvins (see
Figure 2), has also been reported (Krishnamurthy et al., 2011),
confirming the earlier biogenic synthesis of this previously unde-
scribed structure and precursor (Serhan et al., 2000). Impor-
tantly, the stereoselective actions of each SPM have proven
highly effective in regulating human PMN and monocytes in
microfluidic chambers (Jones et al., 2012; Kasuga et al., 2008;
Oh et al., 2012). Together, these clearly establish the direct
actions of these compounds on human cells, where they can
activate specific G protein-coupled receptors and hence their
potential for therapeutic use in man.
Resolvins and lipoxin A4 are present in human breast milk in
high amounts (Weiss et al., 2013), in fish such as salmon (Raatz
et al., 2011), and are produced in humans following supplemen-
tation with omega-3 (EPA, DHA) in peripheral blood at amounts
where they are found to be bioactive in experimental systems
(Mas et al., 2012). Also, they are produced in humans following
strenuous exercise (Markworth et al., 2013) and in human adi-
pose tissue (Cla`ria et al., 2013).
Leukotrienes and Lipoxins: Arachidonic Acid-Derived
Mediators
Alongside omega-3-derived SPMs, arachidonic acid-derived lip-
oxins and their carbon 15 position epimers (Figures 1 and 3) also
exert beneficial actions on inflammation and resolution (Chiang
et al., 2005). Although the LXs were first identified and bio-
synthesized from isolated human leukocytes and eosinophils
(Samuelsson et al., 1987), their functions in inflammation in vivo
remained to be established. For instance, in a rabbit model of
periodontal disease, transgenic overexpression of the 15-LOX
type I is protective of inflammation-induced bone loss and
dermal inflammation via increased production of LXA4monitored
with LC-MS/MS-based identification (Serhan et al., 2003). Also,
treatment with LXA4 following inhaled LPS-induced lung injury
has been demonstrated to limit inflammation (Jin et al., 2007)
and to reduce pro- and anti-inflammatory cytokine production,
enhance macrophage recruitment, reduce blood bacterial
load, and improve mortality in a rat CLP model (Walker et al.,
2011). In the latter study, macrophage recruitment was in-
creased without impairing phagocytic function, and systemic
inflammation reduced without increasing bacterial spread, mir-
roring the actions of resolvins, namely RvE1 and RvD2 (Seki
et al., 2010; Spite et al., 2009; and see references in Table 1).
A similar paradoxical relationship between an attenuated
innate immune response (PMN trafficking to the infected site)
versus increased host-pathogen interaction (as determined by
survival) has been demonstrated in both wild-type mice treated
with MK 886 (a 5-lipoxygenase [5-LOX] inhibitor) and in 5-LOX-
deficient mice (Benjamim et al., 2005). This effect could
be partially replicated if antagonists of cysteinyl-leukotrienes
(cysteinyl-LTs, a family including LTC4 – E4) were given, but
crucially not on antagonism of the classically proinflammatory
leukotriene B4 (LTB4). This elegantly demonstrates the hierarchi-
cal, multifaceted, and often opposing effects of eicosanoids
Figure 3. SPM Actions and Target Cell Type
Shown are the defining actions of SPM in the innate response of interest in immunology and the actions to stimulate termination and resolution. The precursor
essential polyunsaturated fatty acids (AA, EPA, DHA) are converted by leukocytes to separate chemically distinct families of mediators that stimulate active
resolution responses of isolated cell types and tissues in vivo in animal models. Some of the specific target cell types and representative potent actions of the
SPM members from each family of related structures are listed. All of these actions of SPMs are stereoselective and in the picogram-nanogram range potency.
See Serhan and Chiang (2013) and text for further details.
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vention of the cysteinyl-LT’s deleterious effects on the vascula-
ture (and hence host haemodynamics) assumes primacy as
the main cause of benefit in 5-LOX antagonism (or deletion). In
contrast, selective LTB4 inhibition prior to and post cecal ligation
and puncture (CLP) in a model of sepsis appears to have little
effect on vascular tone and permeability, but might have blunted
the innate immune response (specifically neutrophil trafficking),
exacerbating the infective insult (La¨mmermann et al., 2013;
Rios-Santos et al., 2003). Hence the 5-LOX-derived mediators
play critical roles in the physiologic response of the host to
infection.
The complex interplay between AA-derived LM in systemic
inflammation has also been highlighted in recent results showing
that flavocoxid, a dual cyclooxygenase (COX)-2 and 5-LOX in-
hibitor, reduces the expression of NF-kB, COX-2, and 5-LOX
with improved survival in a murine-CLP model (Bitto et al.,
2012). Plasma IL-10 and counterintuitively LXA4 concentrations
were increased while TNF-a, IL-6, LTB4, and PGE2 were
decreased. The authors suggest that LXA4 is biosynthesized in
mice via another biosynthetic route, for example, initiation via
the combined mouse lipoxygenase that carries both 12-LOXand 15-LOX activities in murine systems (a type of 15-LOX found
in humans) when both COX and 5-LOX are inhibited.Whether the
improvement in outcome is due to enhanced proresolution
effects driven by increased LXA4, decreased cytokine storm
(TNF-a and IL-6), augmentation of the immune response via
reducing PGE2 and 5-LOX-derived LTs (discussed below), se-
lective shunting of AA down the COX or LOX pathways (Chen
et al., 1994), or a combination of all the above is unclear.
Both biologically active ATL and aspirin-triggered resolvins
(Serhan, 2007) trigger resolution (Figures 1 and 3) by inhibiting
leukocyte trafficking in a NO-dependent manner in both murine
(Paul-Clark et al., 2004) and human inflammation (Morris et al.,
2009) and by downregulating extracellular release of superoxide
in neutrophils along with macrophage inflammatory peptide 2
and IL-1b production (Serhan, 2007). The importance of ATL
and LXA4 has previously been demonstrated in severe inflamma-
tion: the absence of LXA4 leading to unbridled inflammation and
elevated mortality in animal models of infection due to DC
hypersensitivity. Along these lines, certain parasites can
stimulate supraphysiologic amounts of LXA4 as part of their
highly evolved mechanism to evade the host response (Bannen-
berg et al., 2004; Serhan, 2007). Indeed, administration ofImmunity 40, March 20, 2014 ª2014 Elsevier Inc. 321
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anti-inflammatory, and certain parasites carry their own 15-lip-
oxygenase to presumably act on host substrates. Moreover,
during Mycobacterium tuberculosis infection, 5-lipoxyganse-
derived LXA4 is elevated, dampening T helper 1 (Th1) cell cyto-
kine responses essential for bacterial clearance. Thus, not only
are lipoxins used by infectious agents to parry host-defense re-
sponses, but also inhibitors of their biosynthesis could prove
useful in clearing such recalcitrant infections as tuberculosis
(Bafica et al., 2005).
Prostaglandins and Resolution: It’s Time and Place that
Counts!
Prostaglandins (PGs) derived from COX metabolism of arachi-
donic acid regulate the changes in blood flow required for leuko-
cytes to exit the postcapillary venules (Figure 1) in the initiation
phase, as well as mediate the class switching of lipid mediators
(Levy et al., 2001) required for termination of the acute response
(Figure 2, upper panel), and can exert immunosuppressive
effects through upregulation of intracellular cAMP (Aronoff
et al., 2006; Luo et al., 2004). PGE2 and PGI2, for example,
reduce the ability of inflammatory leukocytes to phagocytose
and kill microorganisms (Aronoff et al., 2004; Rossi et al., 1998;
Weinberg et al., 1985), as well as inhibit the production of
downstream proinflammatory mediators (Aronoff et al., 2007;
Takayama et al., 2002; Xu et al., 2008). In contrast, these PGs
enhance the production of IL-10 (Harizi et al., 2002). Indeed,
overexpression of PGE2 has been reported in a number of con-
ditions associated with increased susceptibility to infection,
including cancer (Starczewski et al., 1984), aging (Hayek et al.,
1997), and cystic fibrosis (Medjane et al., 2005; Strandvik
et al., 1996). Interestingly, PGE2, generated during the onset
phase of inflammation, also indirectly elicits proresolution ac-
tions by switching on the transcription of enzymes required for
the biosynthesis of other classes of bioactive lipids that are
potent proresolution mediators, such as LXs (Levy et al., 2001),
resolvins (Rvs), and protectins (PDs) (Hong et al., 2003; Marche-
selli et al., 2003; Serhan et al., 2000; Serhan et al., 2002).
While PGD2 can elicit immunomodulatory and anti-inflamma-
tory effects in the same manner as described for PGE2 and
PGI2 via ligation to DP1 (Figure 1, upper panel), it can also act
independently of DP1 and DP2 receptor activation when nonen-
zymatically dehydrated into biologically active PGs of the J2
series (e.g., PGJ2, D12,14-PGJ2 and 15-deoxy-D12,14-PGJ2
[15d-PGJ2]) (Diab et al., 2002). These cyclopentenone PGs, as
they are so called, form covalent attachments with reactive sul-
phydryl groups on intracellular regulatory proteins, enabling
them to modulate their function (Kim et al., 2006; Oliva et al.,
2003; Renedo et al., 2007). 15d-PGJ2 for example, via ligation
to the nuclear receptor PPAR-g (Khan, 1995), decreases proin-
flammatory cytokine release and modifies gene expression (Ric-
ote et al., 1998), as well as directly inhibits the actions of IkB
kinase (IKK), the kinase responsible for the activation of NF-kB
(Cernuda-Morollo´n et al., 2001; Straus et al., 2000). Independent
of PPAR-g, 15d-PGJ2 can preferentially inhibit monocyte rather
than neutrophil trafficking through differential regulation of cell-
adhesion molecule and chemokine expression (Gilroy et al.,
2003; Pasceri et al., 2000), regulate macrophage activation
and proinflammatory gene expression (Lawrence, 2002), and
induce leukocyte apoptosis through a caspase-dependent322 Immunity 40, March 20, 2014 ª2014 Elsevier Inc.mechanism (Bishop-Bailey and Hla, 1999; Gilroy et al., 2003;
Lawrence et al., 2001). Moreover, it has been illustrated that
PGD2-derived compounds act as endogenous braking signals
for lymphocytes to stimulate resolution (Trivedi et al., 2006).
It is now clear that the inflammatory program contains key
checkpoints and temporal and spatial switches that regulate
its onset, maintenance, and resolution. It turns out that the reso-
lution phase of inflammation is just as actively orchestrated and
carefully choreographed as its induction andmaintenance. A key
finding in recent years is that the biosynthetic pathways required
for inflammation to resolve often require the prior production of
lipid mediators that are produced locally during the initiation of
acute inflammatory response. In particular, PGE2 and PGD2,
which are responsible for inflammation induction, subsequently
stimulate anti-inflammatory circuits by inducing 15-LOX in neu-
trophils. This class switch in eicosanoid production, from LTs
and PGs to lipoxins (Levy et al., 2001), provides temporal and
spatial check points during the inflammatory cascade (the lipid
mediator class switch is illustrated in Figure 1).
Whereas the anti-inflammatory prostanoids (e.g., PGD2 and
PGE2) can limit the extent of inflammation, they and their metab-
olites can also stimulate active tissue remodeling and repair; in
other words, class switching might not always be required for
resolution to be initiated. Within a single pathway of the eicosa-
noid family initiated by COX-2 and subsequently regulated by the
enzyme hematopoietic PGD2 synthase (hPGD2S), proresolving
mediators PGD2 and 15d-PGJ2 are produced at sufficient
amounts in vivo (Figure 1, upper panel) to drive the resolution
of acute inflammation (Rajakariar et al., 2007).
Abandoned for over 15 years primarily due to one null random-
ized-controlled trial (Bernard et al., 1997), the concept of COX
inhibition, and hence lipid mediator manipulation in severe in-
flammatory states, is regaining traction (Aronoff, 2012; Eisen,
2012). A key factor in this has been the recent publication of mul-
tiple observational data sets relating predominantly aspirin and
statin administration, but also nonsteroidal anti-inflammatory
agents (NSAIDs), to clinical benefit. This information, coupled
with a more advanced appreciation of how inflammatory resolu-
tion pathways, and local-acting lipid mediators in particular,
might impact immune competence, necessitates a careful clin-
ical reappraisal of validity of these drugs.
Cells of the Resolution Cascade
Inflammation does not occur in isolation, but in distinct organs
with quite different anatomical locations and physiological func-
tions. The architecture of organs is very closely adapted to their
function. Tissue-resident stromal cells such as fibroblasts, endo-
thelial, and epithelial cells define themicroanatomy and architec-
ture of organs and provide the appropriate microenvironment in
which specialized immune functions can occur. In addition to
their landscaping properties, these stromal cells are not just pas-
sive players in immune-mediated inflammatory responses but
play an active role in governing the persistence of inflammatory
disease, as well as enabling immunological memory to become
established in a site-specific manner (Hammerschmidt et al.,
2008). The response of the immune system to tissue damage in-
volves a carefully choreographed series of cellular interactions
between immune and nonimmune cells (Figure 1). Immune cells
require stromal cells in order to home to and survive within the
site of inflammation. Given that all inflammatory reactions take
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understanding the biology of both hematopoietic and nonhema-
topoietic cells is important in understanding how inflammatory
cell infiltrates become established and persistent in chronic
immune-mediated inflammatory diseases.
Several specialized cell phenotypes have been implicated in
the resolution of inflammation (Figure 1). Monocyte-derived
macrophages in particular exhibit a wide-range of phenotypic
plasticity, the origins of which lie in specific tissue- and hemato-
poietic cell-derived stimuli (Sica and Mantovani, 2012). These
lineage subtypes might exert a wide range of effects both pro-
and anti-inflammatory, beneficial and detrimental, in diverse dis-
ease states (Mantovani et al., 2004) and in response to different
pathogens (Me`ge et al., 2011). Our group has recently described
a previously unknown resolution-phase macrophage denoted
rM that possesses a hybrid phenotype of alternative activation,
mannose receptor expression, and synthesis of IL-10 and argi-
nase 1 (classically M2, anti-inflammatory [Gordon, 2003]) with
high COX2 and iNOS expression (classically M1, proinflamma-
tory) (Bystrom et al., 2008). This rM phenotype, inducible by
elevating intracellular cAMP, is vital in encouraging innate-type
lymphocyte repopulation of inflamed cavities (Bystrom et al.,
2008), a key step in restoring tissue homeostasis and controlling
responses to secondary infective challenge (Rajakariar et al.,
2008). Transcriptomic analysis of rM has suggested a potential
role in antigen processing and presentation, T and B lymphocyte
recruitment, termination of inflammatory cell trafficking, and
clearance, but also highlighted the naivety of attempting to
rigidly define and categorize such plastic cells in a dynamic envi-
ronment (Stables et al., 2011).
Medeiros and colleagues (Medeiros et al., 2009) have shown
that the efferocytosis of apoptotic cells by activated macro-
phages causes suppression of Fcg receptor-mediated phagocy-
tosis and bacterial killing by an autocrine and/or paracrine PGE2
mechanism in the lung. E-prostanoid 2 (EP2) receptor-mediated
elevation of intracellular cAMP appeared to be the primary
pathway with apoptotic cell-induced functional impairment,
being reversed with aspirin or indomethacin pretreatment and
direct EP2-receptor antagonists (Medeiros et al., 2009). Other
authors have implicated transforming growth factor b (TGF-b)
(Freire-de-Lima et al., 2006), potentially via PGE2 again (directly
or indirectly (Diaz et al., 1989)) or 15-LOX-derived LXA4 (Freire-
de-Lima et al., 2006), and an interferon-g (IFN-g) activated NO
mechanism (Ren et al., 2008) as the soluble immunosuppressive
mediators involved in the effect of apoptotic cells on phagocytes
and their resultant function. This heterogeneity indicates that the
exact pathway of apoptotic cell immune regulation is pleiotropic
and might depend on the type and activation state of the effero-
cytosing phagocyte (Dalli and Serhan, 2012; Medeiros et al.,
2009; Ryan and Godson, 2010).
More recent, as-yet-unpublished results have highlighted
that these cells are phenotypically similar to myeloid-derived
suppressor cells (MDSCs). In mice, MDSCs represent a hetero-
geneous group of GR-1+CD11b+ cells, composed of both
granulocytic and monocytic subsets—the precursors of neutro-
phils, macrophages, and dendritic cells (DCs) (Gabrilovich and
Nagaraj, 2009). They are notable for their potent ability to sup-
press T cell proliferation and responses, in particular Th1 cells,
through production of nitric oxide and reactive oxygen species(especially peroxynitrite), and for their expression upon activa-
tion of immune suppressive inducible nitric oxide synthase, argi-
nase, and a range of both pro and anti-inflammatory cytokines
(Gabrilovich and Nagaraj, 2009). They might also induce the de
novo development of T regulatory (Treg) cells (Huang et al.,
2006).
Like MDSCs, Treg cells have an increasingly appreciated role
in inflammatory resolution (Venet et al., 2008). These CD4+
T cells are characterized by high surface expression of CD25
(IL-2Ra chain), the T cell inhibitory receptor CTL-associated
antigen 4 (CTLA-4), the glucocorticoid-induced TNF receptor
(GITR), and the transcriptional regulator forkhead box p3
(Foxp3+), the latter correlating with Treg cell suppressive activity
(Campbell and Ziegler, 2007). Treg cells might be subdivided into
natural and induced (or adaptive) Treg cells. The former arises
during the normal process of maturation in the thymus, the latter
developing from conventional CD4+CD25 T cells in the periph-
ery under specific stimulatory conditions elicited by infection and
collateral tissue damage (Bluestone and Abbas, 2003). At the site
of inflammation, Treg cells exert three major immunomodulatory
effects: direct killing of cytotoxic cells, inhibition of proinflamma-
tory cytokine secretion by cytotoxic cells (especially IL-2 and
TNF-a), and secretion of anti-inflammatory cytokines (notably
TGF-b and IL-10) (Kessel et al., 2009). Classically studied
in the setting of chronic infection, the potential for Treg cell
numbers, activation, and functional capacity to influence the
outcome of pathogen-host interactions is well established
(Belkaid and Rouse, 2005). Their role in the resolution of organ-
specific autoimmune inflammation and ability to attenuate sub-
sequent reactions has recently been described (Rosenblum
et al., 2011), whereas in LPS-induced acute lung injury, depletion
of Treg cells has been associated with worse outcomes
(D’Alessio et al., 2009) as was abolition of their chemotactic
gradient (Wang et al., 2012).
Implications for Treatment: Resolution of Inflammation
without Immune Suppression?
It is now increasingly clear that the inflammatory cascade has a
number of tactically placed controllers and checkpoints that
limit the magnitude and duration of its response. However,
the identification, isolation and molecular dissection of the
new families of specialized proresolving mediators described
in this review (Figure 3) will encourage a move away from
focusing on the development of yet more anti-inflammatory,
potentially ‘‘resolution toxic’’ drugs toward those that are ‘‘res-
olution friendly’’ replacement therapies (Chiang et al., 2008;
Gilroy et al., 2004; Schwab et al., 2007). While the total organic
synthesis of the natural SPM is challenging and costly,
requiring many steps, the syntheses as well as those of biolog-
ically and chemically stable mimetics have been achieved
(O’Sullivan et al., 2007; Serhan and Petasis, 2011). Along these
lines, a resolvin E1 mimetic that has performed well in Phase I
and II clinical trials in patients with ocular inflammation is
currently in Phase III clinical trial (http://www.anidapharma.
com/science.html; http://www.auventx.com/auven/products/
RX10045.php; http://www.resolvyx.com/news-pubs/releases/
050108.asp; http://www.resolvyx.com). Other SPMs, including
PD1 and MaR1, are also in clinical development programs
with the goal of stimulating the endogenous resolution pro-
grams of inflammation.Immunity 40, March 20, 2014 ª2014 Elsevier Inc. 323
Immunity
ReviewAlthough the SPMs and proresolving prostaglandins are
attractive new therapeutic targets, they have some inherent
pharmacological limitations that will need to be overcome before
they can be easily adopted for clinical use. For example, time of
administration in the inflammatory cascade might turn out to be
critical, particularly because the tight spatial and temporal regu-
lation of prostaglandins might be difficult to recapitulate in
humans, where timing the start of an inflammatory insult can
be challenging. It remains unclear whether the SPMs and prore-
solving prostaglandins will have any therapeutic efficacy in
chronic persistent inflammation as opposed to acute, potentially
resolving inflammatory conditions such as sepsis. Equally,
although the differential role of lipid mediators in host defense
is becoming increasingly appreciated, it must be emphasized
that certain families including lipoxins and resolvins can each
prime leukocytes for bacterial killing, while others, namely pros-
taglandins, impair this process. Considering results from
research on tuberculosis infections (Bafica et al., 2005), it might
be possible to tailor lipid mediators, their mimetics, and/or inhib-
itors of lipidmediator biosynthetic pathways in specific cell types
to tackle certain classes of bacterial infections.
Developing new proresolving agents will mean producing
stable, cost-effective pharmacological agents that limit leuko-
cyte (e.g., PMN) traffic, encourage PMN apoptosis at sites of
inflammation and tissue injury, as well as clearance, and help
restore the stromal microenvironment to its preinflammatory
state. This is likely to benefit patients with defects in the
resolution of a range of diseases not only including inflamma-
tion but also infection and possibly cancer. But such an
approach will require a change in philosophy away from inhibi-
tion and depletion strategies toward activation and replacement.
It will also require a search for defects in the resolution of
inflammation in clinical settings: leaky resolution as the cause
of persistent disease rather than the lack of sufficient anti-inflam-
matory therapy. Perhaps only then will the next generation of
compounds, namely immunoresolvents, with the potency and
proresolving mechanisms of aspirin and steroids, but without
the crippling side effects of bleeding and immune suppression,
emerge.
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